Sebastiaan Heidt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5602212/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clinical and Experimental Immunology, 2009, 159, 199-207.	1.1	132
2	B Cell Repopulation After Alemtuzumab Induction—Transient Increase in Transitional B Cells and Long-Term Dominance of NaÃ⁻ve B Cells. American Journal of Transplantation, 2012, 12, 1784-1792.	2.6	114
3	Effects of Immunosuppressive Drugs On Purified Human B Cells: Evidence Supporting the Use of MMF and Rapamycin. Transplantation, 2008, 86, 1292-1300.	0.5	105
4	The impact of Th17 cells on transplant rejection and the induction of tolerance. Current Opinion in Organ Transplantation, 2010, 15, 456-461.	0.8	100
5	Extensive Cross-Reactivity of CD4 + Adenovirus-Specific T Cells: Implications for Immunotherapy and Gene Therapy. Journal of Virology, 2003, 77, 6562-6566.	1.5	84
6	The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients. Transplant Immunology, 2015, 33, 51-57.	0.6	82
7	Regulatory B cells: Phenotype, function and role in transplantation. Transplant Immunology, 2017, 41, 1-9.	0.6	69
8	Peripheral Blood Sampling for the Detection of Allograft Rejection: Biomarker Identification and Validation. Transplantation, 2011, 92, 1-9.	0.5	68
9	Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant. American Journal of Transplantation, 2018, 18, 2274-2284.	2.6	65
10	A Novel ELISPOT Assay to Quantify HLA-Specific B Cells in HLA-Immunized Individuals. American Journal of Transplantation, 2012, 12, 1469-1478.	2.6	64
11	Th17: Contributors to Allograft Rejection and a Barrier to the Induction of Transplantation Tolerance?. Transplantation, 2011, 91, 939-945.	0.5	63
12	PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. Frontiers in Immunology, 2018, 9, 321.	2.2	63
13	Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study. Journal of Translational Medicine, 2015, 13, 344.	1.8	59
14	<scp>HLAâ€EMMA</scp> : A userâ€friendly tool to analyse <scp>HLA</scp> class I and class <scp>II</scp> compatibility on the amino acid level. Hla, 2020, 96, 43-51.	0.4	53
15	Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients. Kidney International, 2018, 93, 491-500.	2.6	52
16	Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms. Immunogenetics, 2017, 69, 631-641.	1.2	50
17	Blood cell mRNAs and microRNAs: optimized protocols for extraction and preservation. Blood, 2013, 121, e81-e89.	0.6	49
18	B Cell Immunity in Solid Organ Transplantation. Frontiers in Immunology, 2016, 7, 686.	2.2	49

#	Article	IF	CITATIONS
19	Antibodies against ARHGDIB are associated with long-term kidney graft loss. American Journal of Transplantation, 2019, 19, 3335-3344.	2.6	46
20	Regulatory T Cells in Pregnancy: It Is Not All About FoxP3. Frontiers in Immunology, 2020, 11, 1182.	2.2	42
21	Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients. Journal of Translational Medicine, 2014, 12, 331.	1.8	41
22	Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. Kidney International, 2015, 87, 1230-1240.	2.6	39
23	Proteasome Inhibition Profoundly Affects Activated Human B Cells. Transplantation, 2013, 95, 1331-1337.	O.5	38
24	Novel aspects of epitope matching and practical application in kidney transplantation. Kidney International, 2018, 93, 314-324.	2.6	37
25	Defining the immunogenicity and antigenicity of <scp>HLA</scp> epitopes is crucial for optimal epitope matching in clinical renal transplantation. Hla, 2017, 90, 5-16.	0.4	36
26	The long and winding road towards epitope matching in clinical transplantation. Transplant International, 2019, 32, 16-24.	0.8	35
27	Quantification of HLA class II-specific memory B cells in HLA-sensitized individuals. Human Immunology, 2015, 76, 129-136.	1.2	34
28	An Easy and Sensitive Method to Profile the Antibody Specificities of HLA–specific Memory B Cells. Transplantation, 2019, 103, 716-723.	0.5	34
29	Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study. American Journal of Transplantation, 2020, 20, 2905-2915.	2.6	34
30	Tissue-specific endothelial cell heterogeneity contributes to unequal inflammatory responses. Scientific Reports, 2021, 11, 1949.	1.6	34
31	Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients. American Journal of Transplantation, 2019, 19, 2926-2933.	2.6	32
32	A Memory B Cell Crossmatch Assay for Quantification of Donor-Specific Memory B Cells in the Peripheral Blood of HLA-Immunized Individuals. American Journal of Transplantation, 2017, 17, 2617-2626.	2.6	31
33	Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival. Transplantation, 2019, 103, 789-797.	0.5	31
34	Cross-Reactivity of Virus-Specific CD8+ T Cells Against Allogeneic HLA-C: Possible Implications for Pregnancy Outcome. Frontiers in Immunology, 2018, 9, 2880.	2.2	29
35	Biomarkers of operational tolerance in solid organ transplantation. Expert Opinion on Medical Diagnostics, 2012, 6, 281-293.	1.6	28
36	Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clinical and Experimental Immunology, 2009, 158, 99-105.	1.1	27

#	Article	IF	CITATIONS
37	B Cell Markers of Operational Tolerance Can Discriminate Acute Kidney Allograft Rejection From Stable Graft Function. Transplantation, 2015, 99, 1058-1064.	0.5	25
38	Monitoring B cell subsets and alloreactivity in kidney transplantation. Transplantation Reviews, 2015, 29, 45-52.	1.2	25
39	Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients. Frontiers in Immunology, 2018, 9, 3002.	2.2	25
40	Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure. Journal of the American Society of Nephrology: JASN, 2018, 29, 2279-2285.	3.0	25
41	Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR. American Journal of Transplantation, 2020, 20, 3341-3353.	2.6	25
42	Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study. American Journal of Transplantation, 2021, 21, 3055-3065.	2.6	25
43	Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets. Haematologica, 2019, 104, 403-416.	1.7	23
44	Donor-specific B Cell Memory in Alloimmunized Kidney Transplant Recipients: First Clinical Application of a Novel Method. Transplantation, 2020, 104, 1026-1032.	0.5	23
45	Highly Sensitized Patients Are Well Served by Receiving a Compatible Organ Offer Based on Acceptable Mismatches. Frontiers in Immunology, 2021, 12, 687254.	2.2	23
46	Polyclonal B cell activation for accurate analysis of pre-existing antigen-specific memory B cells. Clinical and Experimental Immunology, 2014, 177, 333-340.	1.1	22
47	A subset of anti-HLA antibodies induces Fcl̂³Rlla-dependent platelet activation. Haematologica, 2018, 103, 1741-1752.	1.7	21
48	Ischemia-Reperfusion Injury Accelerates Human Antibody-Mediated Transplant Vasculopathy. Transplantation, 2013, 96, 139-145.	0.5	20
49	Detecting the Humoral Alloimmune Response. Transplantation, 2015, 99, 908-915.	0.5	20
50	Beneficial Immune Effects of Myeloid-Related Proteins in Kidney Transplant Rejection. American Journal of Transplantation, 2016, 16, 1441-1455.	2.6	20
51	Monitoring of indirect allorecognition: wishful thinking or solid data?. Tissue Antigens, 2008, 71, 1-15.	1.0	19
52	Visualizing Dynamic Changes at the Maternal-Fetal Interface Throughout Human Pregnancy by Mass Cytometry. Frontiers in Immunology, 2020, 11, 571300.	2.2	19
53	A Comprehensive Evaluation of the Antibody-Verified Status of Eplets Listed in the HLA Epitope Registry. Frontiers in Immunology, 2021, 12, 800946.	2.2	18
54	Pretransplant Serum CXCL9 and CXCL10 Levels Fail to Predict Acute Rejection in Kidney Transplant Recipients Receiving Induction Therapy. Transplantation, 2011, 91, e59-e61.	0.5	17

#	Article	IF	CITATIONS
55	Transplantation in highly sensitized patients: challenges and recommendations. Expert Review of Clinical Immunology, 2018, 14, 673-679.	1.3	17
56	Increased HLA-G Expression in Term Placenta of Women with a History of Recurrent Miscarriage Despite Their Genetic Predisposition to Decreased HLA-G Levels. International Journal of Molecular Sciences, 2019, 20, 625.	1.8	17
57	A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. Nephrology Dialysis Transplantation, 2019, 34, 1056-1063.	0.4	17
58	Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets. Haematologica, 2022, 107, 2432-2444.	1.7	17
59	What is wrong with the regulatory T cells and foetomaternal tolerance in women with recurrent miscarriages?. Hla, 2016, 87, 69-78.	0.4	16
60	A Europe wide acceptable mismatch program will enable transplantation of long waiting highly sensitised patients with a compatible donor. Transplant Immunology, 2021, 64, 101354.	0.6	16
61	How can we reduce costs of solidâ€phase multiplexâ€bead assays used to determine antiâ€ <scp>HLA</scp> antibodies?. Hla, 2016, 88, 110-119.	0.4	15
62	How the definition of acceptable antigens and epitope analysis can facilitate transplantation of highly sensitized patients with excellent long-term graft survival. Current Opinion in Organ Transplantation, 2018, 23, 493-499.	0.8	15
63	The development of preeclampsia in oocyte donation pregnancies is related to the number of fetal-maternal HLA class II mismatches. Journal of Reproductive Immunology, 2020, 137, 103074.	0.8	14
64	Implementation of molecular matching in transplantation requires further characterization of both immunogenicity and antigenicity of individual HLA epitopes. Human Immunology, 2022, 83, 256-263.	1.2	14
65	T-cell alloreactivity and transplantation outcome. Current Opinion in Organ Transplantation, 2015, 20, 454-460.	0.8	13
66	Technical challenges and clinical relevance of single antigen bead C1q/C3d testing and IgG subclass analysis of human leukocyte antigen antibodies. Transplant International, 2018, 31, 1189-1197.	0.8	13
67	Soluble HLAâ€G levels in seminal plasma are associated with HLAâ€G 3′UTR genotypes and haplotypes. Hla, 2019, 94, 339-346.	0.4	13
68	Towards the identification of the relative immunogenicity of individual HLA antibody epitopes. Human Immunology, 2019, 80, 218-220.	1.2	13
69	HLAâ€specific memory Bâ€cell detection in kidney transplantation: Insights and future challenges. International Journal of Immunogenetics, 2020, 47, 227-234.	0.8	13
70	Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donorâ€specific antibodies. Hla, 2019, 94, 415-424.	0.4	11
71	Pre-existing Alloreactive T and B Cells and Their Possible Relevance for Pre-transplant Risk Estimation in Kidney Transplant Recipients. Frontiers in Medicine, 2020, 7, 340.	1.2	11
72	Not all HLA epitope mismatches are equal. Kidney International, 2020, 97, 653-655.	2.6	11

#	Article	IF	CITATIONS
73	Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients. Transplantation Direct, 2017, 3, e124.	0.8	10
74	Presence of intragraft B cells during acute renal allograft rejection is accompanied by changes in peripheral blood B cell subsets. Clinical and Experimental Immunology, 2019, 196, 403-414.	1.1	10
75	Epitope-Based HLA Matching. Transplantation, 2017, 101, 1744-1745.	0.5	9
76	No Evidence for Cross-reactivity of Virus-specific Antibodies With HLA Alloantigens. Transplantation, 2018, 102, 1844-1849.	0.5	9
77	The number of FoxP3 regulatory T cells in the circulation may be a predictive biomarker for kidney transplant recipients: A multistage systematic review. International Immunopharmacology, 2018, 65, 483-492.	1.7	9
78	Virtual crossmatching for deceased donor transplantation becomes reality. Kidney International, 2020, 97, 657-659.	2.6	9
79	Principles of Virtual Crossmatch Testing for Kidney Transplantation. Kidney International Reports, 2022, 7, 1179-1188.	0.4	9
80	Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation. Frontiers in Immunology, 2022, 13, .	2.2	9
81	T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation. Frontiers in Immunology, 2021, 12, 784040.	2.2	8
82	HLA-DQ-Specific Recombinant Human Monoclonal Antibodies Allow for In-Depth Analysis of HLA-DQ Epitopes. Frontiers in Immunology, 2021, 12, 761893.	2.2	8
83	Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients. Nephrology Dialysis Transplantation, 2019, 34, 1417-1422.	0.4	7
84	Reciprocal HLA-DR allogenicity between mother and child affects pregnancy outcome parameters. Journal of Reproductive Immunology, 2019, 133, 15-17.	0.8	6
85	Standard reference sequences for submission of <scp>HLA</scp> genotyping for the 18th International HLA and Immunogenetics Workshop. Hla, 2021, 97, 512-519.	0.4	6
86	A Combined microRNA and Chemokine Profile in Urine to Identify Rejection After Kidney Transplantation. Transplantation Direct, 2021, 7, e711.	0.8	6
87	Comparison of different luminex single antigen bead kits for memory B cellâ€derived <scp>HLA</scp> antibody detection. Hla, 2021, 98, 200-206.	0.4	6
88	Heterologous Immunity of Virus-Specific T Cells Leading to Alloreactivity: Possible Implications for Solid Organ Transplantation. Viruses, 2021, 13, 2359.	1.5	6
89	Got your mother in a whirl: The role of maternal T cells and myeloid cells in pregnancy. Hla, 2020, 96, 561-579.	0.4	5
90	Bortezomib affects the function of human B cells: possible implications for desensitization protocols. Clinical Transplants, 2009, , 387-92.	0.2	5

#	Article	IF	CITATIONS
91	B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. JHEP Reports, 2022, 4, 100460.	2.6	5
92	Minimal data reporting standards for serological testing for histocompatibility. Human Immunology, 2018, 79, 865-868.	1.2	4
93	Effect of seminal plasma on dendritic cell differentiation in vitro depends on the serum source in the culture medium. Journal of Reproductive Immunology, 2020, 137, 103076.	0.8	4
94	Low incidence of IgA isotype of HLA antibodies in alloantigen exposed individuals. Hla, 2021, 97, 101-111.	0.4	4
95	Immunogenetics and immunology of transplantation in Leiden. Transplant Immunology, 2014, 31, 195-199.	0.6	3
96	Evaluating the role of paternal factors in aetiology and prognosis of recurrent pregnancy loss: study protocol for a hospital-based multicentre case–control study and cohort study (REMI III project). BMJ Open, 2019, 9, e033095.	0.8	3
97	A new strategy for systematically classifying <scp>HLA</scp> alleles into serological specificities. Hla, 2022, 100, 193-231.	0.4	3
98	Relating the number of human leucocytes antigen mismatches to pregnancy complications in oocyte donation pregnancies: study protocol for a prospective multicentre cohort study (DONOR study). BMJ Open, 2019, 9, e027469.	0.8	2
99	B Cell Repopulation after Alemtuzumab Treatment in Kidney Transplant Recipients - Transient Increase in Transitional B Cells and Long Term Dominance of NaÃ ⁻ ve B Cells. Transplantation, 2012, 94, 2.	0.5	1
100	OR41 PIRCHE-II: A novel tool to identify permissible HLA mismatches in kidney transplantation. Human Immunology, 2017, 78, 39.	1.2	1
101	A Novel Tool to Define the Immunogenicity of HLA Mismatches. Transplantation, 2018, 102, S157.	0.5	1
102	Data on a new biomarker for kidney transplant recipients: The number of FoxP3 regulatory T cells in the circulation. Data in Brief, 2018, 21, 2567-2575.	0.5	1
103	Two Human Monoclonal HLA-Reactive Antibodies Cross-React with Mamu-B*008, a Rhesus Macaque MHC Allotype Associated with Control of Simian Immunodeficiency Virus Replication. Journal of Immunology, 2021, 206, 1957-1965.	0.4	1
104	Innate-like B Cells: Local Drivers of Non-HLA Immunity in Rejecting Kidney Allografts?. Transplantation, 2022, 106, 234-235.	0.5	1
105	Novel strategies for immunological monitoring of kidney transplant recipients: from microRNA to alloantibodies. Clinical Transplants, 2013, , 257-67.	0.2	1
106	Improve in-depth immunological risk assessment to optimize genetic-compatibility and clinical outcomes in child and adolescent recipients of parental donor kidney transplants: protocol for the INCEPTION study. BMC Nephrology, 2021, 22, 416.	0.8	1
107	24-P. Human Immunology, 2006, 67, S74.	1.2	Ο
108	19-OR: The effects of immunosuppressive drugs on in vitro stimulated B cells. Human Immunology, 2007, 68, S110.	1.2	0

#	Article	IF	CITATIONS
109	124-P: The effects of immunosuppressive drugs on T cell dependent B cell cultures. Human Immunology, 2009, 70, S74.	1.2	0
110	A Novel ELISPOT Assay to Quantify HLA-Specific B Cells in HLA-Immunized Individuals. Transplantation, 2012, 94, 354.	0.5	0
111	Preventing Memory B Cell Formation. Transplantation, 2016, 100, 1605-1606.	0.5	0
112	Visualizing the players of the maternal immune response at the maternal-fetal interface by high-dimensional mass cytometry. Placenta, 2017, 57, 244-245.	0.7	0
113	Single antigen testing to reduce early antibody-mediated rejection risk in female recipients of a spousal donor kidney. Transplant Immunology, 2021, 67, 101407.	0.6	0